Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia

Detalhes bibliográficos
Autor(a) principal: Delbuono,Elizabete
Data de Publicação: 2008
Outros Autores: Maekawa,Yumi H., Latorre,Maria do Rosário D. O., Seber,Adriana, Petrilli,Antonio Sergio, Braga,Josefina A. P., Lee,Maria Lúcia M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000400010
Resumo: The detection of minimal residual disease (MRD) is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL) providing crucial information on the response to treatment and risk of relapse. However, the high cost of these techniques restricts their use in countries with limited resources. Thus, we prospectively studied the use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and 28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was defined as > 0.01% cells expressing the aberrant immunophenotype as characterized at diagnosis among total events in the sample. A total of 87% of the patients had an aberrant immunophenotype at diagnosis. On d14, 56% of the BM and 43% of the PB samples had detectable MRD. On d28, this decreased to 45% and 31%, respectively. The percentage of cells with the aberrant phenotype was similar in both BM and PB in T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL. Moreover, MRD was detected in the BM of patients in complete morphological remission (44% on d14 and 39% on d28). MRD was not significantly associated to gender, age, initial white blood cell count or cell lineage. This FC assay is feasible, affordable and readily applicable to detect MRD in centers with limited resources.
id ABHHTC-1_bceecd1a0ffccdc6b0d2bb984fb7141f
oai_identifier_str oai:scielo:S1516-84842008000400010
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemiaMinimal residual diseaseacute lymphoblastic leukemiaflow cytometrychildrenperipheral bloodThe detection of minimal residual disease (MRD) is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL) providing crucial information on the response to treatment and risk of relapse. However, the high cost of these techniques restricts their use in countries with limited resources. Thus, we prospectively studied the use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and 28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was defined as > 0.01% cells expressing the aberrant immunophenotype as characterized at diagnosis among total events in the sample. A total of 87% of the patients had an aberrant immunophenotype at diagnosis. On d14, 56% of the BM and 43% of the PB samples had detectable MRD. On d28, this decreased to 45% and 31%, respectively. The percentage of cells with the aberrant phenotype was similar in both BM and PB in T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL. Moreover, MRD was detected in the BM of patients in complete morphological remission (44% on d14 and 39% on d28). MRD was not significantly associated to gender, age, initial white blood cell count or cell lineage. This FC assay is feasible, affordable and readily applicable to detect MRD in centers with limited resources.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2008-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000400010Revista Brasileira de Hematologia e Hemoterapia v.30 n.4 2008reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1590/S1516-84842008000400010info:eu-repo/semantics/openAccessDelbuono,ElizabeteMaekawa,Yumi H.Latorre,Maria do Rosário D. O.Seber,AdrianaPetrilli,Antonio SergioBraga,Josefina A. P.Lee,Maria Lúcia M.eng2008-10-28T00:00:00Zoai:scielo:S1516-84842008000400010Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2008-10-28T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
spellingShingle Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
Delbuono,Elizabete
Minimal residual disease
acute lymphoblastic leukemia
flow cytometry
children
peripheral blood
title_short Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_full Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_fullStr Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_full_unstemmed Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_sort Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
author Delbuono,Elizabete
author_facet Delbuono,Elizabete
Maekawa,Yumi H.
Latorre,Maria do Rosário D. O.
Seber,Adriana
Petrilli,Antonio Sergio
Braga,Josefina A. P.
Lee,Maria Lúcia M.
author_role author
author2 Maekawa,Yumi H.
Latorre,Maria do Rosário D. O.
Seber,Adriana
Petrilli,Antonio Sergio
Braga,Josefina A. P.
Lee,Maria Lúcia M.
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Delbuono,Elizabete
Maekawa,Yumi H.
Latorre,Maria do Rosário D. O.
Seber,Adriana
Petrilli,Antonio Sergio
Braga,Josefina A. P.
Lee,Maria Lúcia M.
dc.subject.por.fl_str_mv Minimal residual disease
acute lymphoblastic leukemia
flow cytometry
children
peripheral blood
topic Minimal residual disease
acute lymphoblastic leukemia
flow cytometry
children
peripheral blood
description The detection of minimal residual disease (MRD) is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL) providing crucial information on the response to treatment and risk of relapse. However, the high cost of these techniques restricts their use in countries with limited resources. Thus, we prospectively studied the use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and 28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was defined as > 0.01% cells expressing the aberrant immunophenotype as characterized at diagnosis among total events in the sample. A total of 87% of the patients had an aberrant immunophenotype at diagnosis. On d14, 56% of the BM and 43% of the PB samples had detectable MRD. On d28, this decreased to 45% and 31%, respectively. The percentage of cells with the aberrant phenotype was similar in both BM and PB in T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL. Moreover, MRD was detected in the BM of patients in complete morphological remission (44% on d14 and 39% on d28). MRD was not significantly associated to gender, age, initial white blood cell count or cell lineage. This FC assay is feasible, affordable and readily applicable to detect MRD in centers with limited resources.
publishDate 2008
dc.date.none.fl_str_mv 2008-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000400010
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000400010
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-84842008000400010
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.30 n.4 2008
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213109033074688